The ENRICH trial compared the outcomes between early surgical intervention using the BrainPath® Approach (i.e., MIPS) and a medically managed cohort. The integrated surgical approach included a combination of available technologies, including the FDA-cleared NICO BrainPath® for non-disruptive access and NICO Myriad® to achieve the goal of maximum clot evacuation. Alex Reynolds is joined by the ENRICH trial PIs, Gustavo Pradilla, Jonathan Ratcliff, and Alex Hall plus guests Chris Kellner and Kara Melmed to discuss the findings of the ENRICH clinical trial.